Limits...
High SLFN11 expression predicts better survival for patients with KRAS exon 2 wild type colorectal cancer after treated with adjuvant oxaliplatin-based treatment.

Deng Y, Cai Y, Huang Y, Yang Z, Bai Y, Liu Y, Deng X, Wang J - BMC Cancer (2015)

Bottom Line: SLFN11 high expression was found in 16.9 % of patients, and KRAS exon 2 mutation was detected in 32.2 % of patients.These patients had significantly better overall survival (OS) than those with SLFN11 low expression tumors (100 % vs 78.2 %, log rank P = 0.048).However, among patients with KRAS exon 2 mutant tumors, OS did not significantly differ between those with SLFN11 high and SLFN11 low tumors (Log rank P = 0.709).

View Article: PubMed Central - PubMed

Affiliation: Department of Medical Oncology, Gastrointestinal Hospital, Sun Yat-sen Universtiy, Guangzhou, 510655, China. dengyanh@mail.sysu.edu.cn.

ABSTRACT

Background: SLFN11 was reported to be a predictive marker for DNA damage drugs. The study was to investigate whether SLFN11 expression is related to sensitivity to adjuvant oxaliplatin-based treatment in colorectal cancer.

Methods: A tissue microarray, made with specimens from consecutive 261 patients who received oxaliplatin based adjuvant chemotherapy, was stained with anti-SLFN11 antibody. The staining was dichotomized as high or low expression. SLFN11 expression was correlated to clinicopathological factors, KRAS exon 2 mutation and survival.

Results: SLFN11 high expression was found in 16.9 % of patients, and KRAS exon 2 mutation was detected in 32.2 % of patients. SLFN11 was expressed more common in well/moderate differentiation tumors(comparing to poor differentiation ones, 21 % v 4.9 %, P = 0.003) and stage II tumors(comparing to stage III tumors, 26.1 % v 11.4 %,p = 0.006). 23 out of 153 patients with KRAS exon 2 wild-type CRC had SLFN11 high expression, no death events was recorded in the 23 patients until last follow up. These patients had significantly better overall survival (OS) than those with SLFN11 low expression tumors (100 % vs 78.2 %, log rank P = 0.048). However, among patients with KRAS exon 2 mutant tumors, OS did not significantly differ between those with SLFN11 high and SLFN11 low tumors (Log rank P = 0.709).

Conclusions: SLFN11 expression predicts good better survival in colorectal cancer patients with KRAS exon 2 wild type who have received oxaliplatin based adjuvant chemotherapy.

No MeSH data available.


Related in: MedlinePlus

Among patients with KRAS wild-type tumors, those with high SLFN11 expression had significantly longer survival than patients with low SLFN11-expressing ones (Log rank P = 0.048) (a). However, among patients with mutated KRAS tumors, those with high SLFN11 expression had almost the same survival as patients with low SLFN11-expressing ones(Log rank P = 0.709) (b)
© Copyright Policy - OpenAccess
Related In: Results  -  Collection

License 1 - License 2
getmorefigures.php?uid=PMC4631086&req=5

Fig3: Among patients with KRAS wild-type tumors, those with high SLFN11 expression had significantly longer survival than patients with low SLFN11-expressing ones (Log rank P = 0.048) (a). However, among patients with mutated KRAS tumors, those with high SLFN11 expression had almost the same survival as patients with low SLFN11-expressing ones(Log rank P = 0.709) (b)

Mentions: Among 237 patients, 216 had available KRAS and survival data. The DFS and OS according to KRAS exon 2 status or SLFN11 expression status was shown in Table 2. In the cohort, 63 out of 216 had KRAS exon 2 mutated (KRAS-mt) CRC. OS for patients with KRAS exon 2 wild type (KRAS-wt) and KRAS-mt tumors was almost identical (80.6 % vs 82.8 %, Log Rank P = 0.823). If OS for the KRAS-wt group were analyzed separately from the KRAS-mt group in Kaplan–Meier analysis, overall survival curves of patients with SLFN11high tumors and those with SLFN11low tumors separated significantly (100 % vs 78.2 %, P = 0.048, Fig. 3a); the SLFN11high group had longer survival. In contrast, in the KRAS-mt group, patients with SLFN11high or SLFN11low tumors did not significantly differ in OS (81.9 % vs 80.2 %, P = 0.709, Fig. 3b). Among 23 KRAS-wt and SLFN11 high expression patients, Only 2 recurrences were detected and no death was recorded. As SLFN11high expression was more common in stage II. We did additional subgroup analysis according to the stage, in patients KRAS-wt tumors and found patients with SLFN11high tumors had a trend of better survival than that with SLFN11low tumors in both stage II (Fig. 4a) and stage III CRC, more prominent in stage III (100 % vs 72 %, Log-rank P = 0.092, Fig. 4b). NRAS and BRAF mutation was tested in KRAS exon 2 wild type patients, 10 and 3 patients were identified as mutation respectively. The results remained the same after exclude the 13 patients (data not shown).Table 2


High SLFN11 expression predicts better survival for patients with KRAS exon 2 wild type colorectal cancer after treated with adjuvant oxaliplatin-based treatment.

Deng Y, Cai Y, Huang Y, Yang Z, Bai Y, Liu Y, Deng X, Wang J - BMC Cancer (2015)

Among patients with KRAS wild-type tumors, those with high SLFN11 expression had significantly longer survival than patients with low SLFN11-expressing ones (Log rank P = 0.048) (a). However, among patients with mutated KRAS tumors, those with high SLFN11 expression had almost the same survival as patients with low SLFN11-expressing ones(Log rank P = 0.709) (b)
© Copyright Policy - OpenAccess
Related In: Results  -  Collection

License 1 - License 2
Show All Figures
getmorefigures.php?uid=PMC4631086&req=5

Fig3: Among patients with KRAS wild-type tumors, those with high SLFN11 expression had significantly longer survival than patients with low SLFN11-expressing ones (Log rank P = 0.048) (a). However, among patients with mutated KRAS tumors, those with high SLFN11 expression had almost the same survival as patients with low SLFN11-expressing ones(Log rank P = 0.709) (b)
Mentions: Among 237 patients, 216 had available KRAS and survival data. The DFS and OS according to KRAS exon 2 status or SLFN11 expression status was shown in Table 2. In the cohort, 63 out of 216 had KRAS exon 2 mutated (KRAS-mt) CRC. OS for patients with KRAS exon 2 wild type (KRAS-wt) and KRAS-mt tumors was almost identical (80.6 % vs 82.8 %, Log Rank P = 0.823). If OS for the KRAS-wt group were analyzed separately from the KRAS-mt group in Kaplan–Meier analysis, overall survival curves of patients with SLFN11high tumors and those with SLFN11low tumors separated significantly (100 % vs 78.2 %, P = 0.048, Fig. 3a); the SLFN11high group had longer survival. In contrast, in the KRAS-mt group, patients with SLFN11high or SLFN11low tumors did not significantly differ in OS (81.9 % vs 80.2 %, P = 0.709, Fig. 3b). Among 23 KRAS-wt and SLFN11 high expression patients, Only 2 recurrences were detected and no death was recorded. As SLFN11high expression was more common in stage II. We did additional subgroup analysis according to the stage, in patients KRAS-wt tumors and found patients with SLFN11high tumors had a trend of better survival than that with SLFN11low tumors in both stage II (Fig. 4a) and stage III CRC, more prominent in stage III (100 % vs 72 %, Log-rank P = 0.092, Fig. 4b). NRAS and BRAF mutation was tested in KRAS exon 2 wild type patients, 10 and 3 patients were identified as mutation respectively. The results remained the same after exclude the 13 patients (data not shown).Table 2

Bottom Line: SLFN11 high expression was found in 16.9 % of patients, and KRAS exon 2 mutation was detected in 32.2 % of patients.These patients had significantly better overall survival (OS) than those with SLFN11 low expression tumors (100 % vs 78.2 %, log rank P = 0.048).However, among patients with KRAS exon 2 mutant tumors, OS did not significantly differ between those with SLFN11 high and SLFN11 low tumors (Log rank P = 0.709).

View Article: PubMed Central - PubMed

Affiliation: Department of Medical Oncology, Gastrointestinal Hospital, Sun Yat-sen Universtiy, Guangzhou, 510655, China. dengyanh@mail.sysu.edu.cn.

ABSTRACT

Background: SLFN11 was reported to be a predictive marker for DNA damage drugs. The study was to investigate whether SLFN11 expression is related to sensitivity to adjuvant oxaliplatin-based treatment in colorectal cancer.

Methods: A tissue microarray, made with specimens from consecutive 261 patients who received oxaliplatin based adjuvant chemotherapy, was stained with anti-SLFN11 antibody. The staining was dichotomized as high or low expression. SLFN11 expression was correlated to clinicopathological factors, KRAS exon 2 mutation and survival.

Results: SLFN11 high expression was found in 16.9 % of patients, and KRAS exon 2 mutation was detected in 32.2 % of patients. SLFN11 was expressed more common in well/moderate differentiation tumors(comparing to poor differentiation ones, 21 % v 4.9 %, P = 0.003) and stage II tumors(comparing to stage III tumors, 26.1 % v 11.4 %,p = 0.006). 23 out of 153 patients with KRAS exon 2 wild-type CRC had SLFN11 high expression, no death events was recorded in the 23 patients until last follow up. These patients had significantly better overall survival (OS) than those with SLFN11 low expression tumors (100 % vs 78.2 %, log rank P = 0.048). However, among patients with KRAS exon 2 mutant tumors, OS did not significantly differ between those with SLFN11 high and SLFN11 low tumors (Log rank P = 0.709).

Conclusions: SLFN11 expression predicts good better survival in colorectal cancer patients with KRAS exon 2 wild type who have received oxaliplatin based adjuvant chemotherapy.

No MeSH data available.


Related in: MedlinePlus